Etoposide: Discovery and Medicinal Chemistry

Author(s): Philippe Meresse, Elsa Dechaux, Claude Monneret, Emmanuel Bertounesque

Journal Name: Current Medicinal Chemistry

Volume 11 , Issue 18 , 2004

Become EABM
Become Reviewer
Call for Editor


Etoposide is an antitumor agent currently in clinical use for the treatment of small cell lung cancer, testicular cancer and lymphomas. Since the introduction of etoposide in 1971, its mechanism of action and potent antineoplastic activity has served as the impetus for intensive research activities in chemistry and biology. This drug acts by stabilizing a normally transient DNA-topoisomerase II complex, thus increasing the concentration of double-stranded DNA breaks. This phenomenon triggers mutagenic and cell death pathways. The function of topoisomerase II is understood in some detail, as is the mechanism of inhibition of etoposide at a molecular level. Etoposide has shortcomings of limited neoplastic activity against several solid tumors such as non-small cell lung cancer, cross-resistance to MDR tumor cell lines and low bioavailability. The design and synthesis of etoposide analogs is an activity of fundamental interest to the field of cancer chemotherapy. In the first part, this article is a survey of the discovery of etoposide, the DNA topoisomerase II structure and mechanism, and the models for drug-enzyme interaction. The last part is concerned with the search for new etoposide analogs based upon an empirical design.

Keywords: Etoposide, DNA-topoisomerase, double-stranded DNA, neoplastic

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [2443 - 2466]
Pages: 24
DOI: 10.2174/0929867043364531
Price: $65

Article Metrics

PDF: 20